Form 4: Vertex Pharmaceuticals COO Disposes of Shares for Tax Obligations

Stuart A. Arbuckle, Executive Vice President and Chief Operating Officer of Vertex Pharmaceuticals Inc., disposed of 37,243 shares of common stock to satisfy tax withholding obligations.

Summary

• Stuart A. Arbuckle, the Executive Vice President and Chief Operating Officer of Vertex Pharmaceuticals Inc. (VRTX), disposed of 37,243 shares of common stock.
• The transaction occurred on July 1, 2025, at a price of $450.23 per share.
• This disposition was made to satisfy tax withholding obligations, indicated by transaction code 'F'.
• Following this transaction, Mr. Arbuckle directly beneficially owns 63,368 shares of common stock.
• Additionally, Mr. Arbuckle indirectly beneficially owns 140 shares of common stock through a 401(k) plan.

Sentiment

Score: 5

Explanation: The transaction is a routine disposition of shares for tax withholding purposes, which is a neutral event and does not indicate positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

This Form 4 filing details a routine insider transaction for tax purposes, which is common across all industries and does not reflect broader industry trends or competitive dynamics within the pharmaceutical sector.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine tax-related disposition by an executive, not a discretionary sale indicating a change in confidence.

Key Dates

Keywords

Vertex Pharmaceuticals, VRTX, Stuart A Arbuckle, Insider Transaction, Form 4, Stock Disposition, Tax Withholding, Common Stock